Danaher CORP /DE/ 10-Q quarterly reports

Danaher Corporation reported increased sales and net earnings for the third quarter of 2025, but significant impairment charges led to a decline in nine-month net earnings and diluted EPS.

Danaher Corporation reported a substantial decrease in net earnings and operating profit for the second quarter and first half of 2025, primarily driven by a significant intangible asset impairment charge in its Life Sciences segment, despite overall sales growth.

Danaher Corporation's first quarter 2025 sales decreased by 1.0% year-over-year, with core sales remaining flat, as the company navigates currency headwinds and tariff impacts.

Danaher Corporation's third-quarter results show a slight revenue increase but a decrease in earnings, impacted by market conditions and strategic investments.

Danaher Corporation's second-quarter results show a decrease in revenue and core sales, primarily driven by declines in the Biotechnology segment, while the Diagnostics segment showed growth.

Danaher Corporation's first quarter 2024 results show a decrease in core sales, particularly in the Biotechnology segment, impacting overall revenue and profitability.